Nov

19

Penny Stocks to Watch – PURO, PGOG, DPDW, AEMD

Filed Under Biotechnology & Drugs, Chemical Manufacturing, Oil & Gas Operations, Other | 3 Comments

I was doing my research the other day when I found this article below on transworldnews.com.  It talks about four penny stocks that might be worth watching.

Purio Inc. (Symbol: PURO) closed at $0.11. Today announced that it has accepted an invitation to meet with high ranking government officials from a region of West Africa to formally present its water/wastewater technology.

Participating in the meeting, scheduled for Saturday, November 22, will be The United Nations Development Program (UNDP), a number of financial institutions including United Bank of Africa, and a delegation of government dignitaries including The Minister of Presidential and Public Affairs. A private meeting between Purio Executives and the Minister is planned following the main event to discuss possible strategies regarding Purio’s involvement in the country’s development plans.

What They Do: Purio owns proprietary water clarification technology suitable to a broad number of applications including the clarification of surface water, industrial process water and sewage. Purio intends to apply its technology initially to industrial and commercial applications to reclaim water and reduce the need for fresh water in such applications. Purio further intends to use its proprietary technology to produce potable water for commercial and residential use. Purio will commercialize its technology via a number of channels, namely licensing strategic partners to build and sell &/or operate units outside of North America, outright sale of their second generation (patent pending) units to end users and will build, own and operate on a fee for service basis their larger permanent installation units in North America.

Perf Go Green Holdings (Symbol: PGOG) closed at $0.52. Today announced a distribution partnership with United Hardware Distributing Company. A full-line wholesale hardware distributor, United services more than 1,200 retail stores in 18 states and had sales of more than $170 million in 2007.

United Hardware Distributing Company, which has developed a dominant presence in the upper-Midwest, provides a wide range of products, retail programs, and support services to independent retailers. Headquartered in Plymouth, Minnesota, the company is 100% owned by its member-dealers, located in 18 states. United services its members from a 400,000 square foot distribution center located in Milbank, South Dakota. The distribution center stocks a complete merchandise assortment of more than 55,000 items.

What They Do: Perf Go Green Holdings is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green’s corporate name reflects its “Go Green” mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

Deep Down (Symbol: DPDW) closed at $0.38. Today announced unaudited results for the three months and nine months ended September 30, 2008.

Revenue for the three months ended September 30, 2008 increased $6.8 million to $11.7 million, a 140% increase over the same three-month period in 2007. The increase in revenue included $8.5 million from the acquisitions of Mako and Flotation, while our historical service lines had an aggregate reduction in revenue of $1.7 million. The reduction in revenue in historical service lines, compared to the same three-month period in 2007, was impacted by two major engineering and product development projects which were completed prior to the third quarter of 2008. These projects had very low margins, and as such, were discontinued during the third quarter of 2008. The remaining reduction of revenues was a result of customers’ delaying many of their major projects due to the softening of the world oil price and the impact it had on anticipated cash flow of our customers.

Gross profit increased by $4.0 million to $5.3 million for the three months ended September 30, 2008 as compared to the same period last year. Gross margins for the same period improved from 25.8% to 45.5%. The inclusion of Mako and Flotation for the three months ended September 2008 increased the gross profit by $4.8 million while our historical service lines had an aggregate decrease of $0.8 million due to a reduction in revenue for this period as compared to the same period a year ago.

What They Do: Deep Down, Inc. provides products and services to the offshore energy industry to support deepwater exploration, development, and production of oil and gas, and other maritime operations worldwide. The company provides various project engineering and management services, including the design, installation, and retrieval of subsea equipment and systems; connection and termination operations; and commissioning. It also offers installation, retrieval, storage, and management services.

Aethlon Medical (Symbol: AEMD) closed at $0.28. Today announced that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders:

To our Shareholders,

In my September shareholder letter, I referenced that our organization was heading into a pivotal month as we anticipated initial Hepatitis-C (HCV) treatment results from a safety study being conducted at the Fortis Hospital. The Fortis study allowed us the opportunity to enroll and test four HCV patients who each received a series of three, 4-hour Hemopurifier® treatments every other day during the course of five days. When considering the rapid replication of HCV combined with the disease being well established in each patient, we did not have tremendous clinical benefit expectations based on a short-term treatment schedule not optimized to reduce viral load. Much to our surprise, significant viral load reductions were observed in the first three patients. Patient #1 had a 95% reduction in viral load when tested three days post treatment and 89% reduction seven days post treatment. Patient #2 had an 85% reduction of viral load three days post treatment and 50% reduction seven days post treatment. Patient #3 had a 60% reduction of viral load three days post treatment and 83% reduction seven days post treatment. Initial data for the fourth patient has now been received for analysis and will be published in a formal clinical study report.

What They Do: Aethlon Medical, Inc. engages in the research and development of a medical device known as the Hemopurifier that removes harmful substances from the blood.

Click here to read more.

Quote of the Day:
For the final exam, I would take an internet company and say, ‘How much is this worth?’ And anybody that gave me an answer I would flunk. – Warren Buffett

  • Share/Bookmark

May

9

Chemokine Therapeutics

Filed Under Biotechnology & Drugs | Leave a Comment

Chemokine Therapeutics (Symbol: CHKT) is a product-focused biotechnology company that develops drugs that harness the therapeutic potential of stem cells through chemokine pathways.

Chemokines are a new class of cytokines, proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation, and also maturation of cells necessary for fighting infection, as well as tissue repair and regeneration.

Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation.

Being the leader in research in this field, the company currently has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth.

Their main goal is to identify and develop multiple drug candidates for the treatment of cancer, blood disorders, cardiovascular and infectious disease.

Their recent press release states they had successfully reduced primary tumor growth in preclinical models of breast cancer with the treatment of the company’s CHCR4 antagonist and CTCE-9908.

In one study the investigators showed that mice treated with CTCE-9908 had statistically significant reduction of the primary tumor size compared to the control mice over time. At the 5-week and 6-week time points the mice treated with CTCE-9908 had an 86% decrease and 80% decrease in primary tumor growth compared to the control mice, respectively. In a second study, treatment with CTCE-9908 also demonstrated a statistically significant reduction in the rate of metastasis compared to the control group. At the 5-week and 6-week time points, the mice treated with CTCE-9908 had an 89% reduction and 95% reduction in metastatic tumor burden compared to the control mice, respectively.

Isn’t it exciting? Of course, at this moment they’re still far from their goal of creating a super drug that cures cancer. But it’s still pretty encouraging to see their recent experiment has turned out to be a tremendous success. For only 7 cents/share, this stock is definitely a bargain!

Quote of the Day:
My favorite time frame for holding a stock is forever. – Warren Buffett

  • Share/Bookmark

Nov

27

Xenomics might be worth it in a long run..

Filed Under Biotechnology & Drugs | Leave a Comment

Xenomics, Inc. (Symbol: XNOM) is the developer of next-generation molecular diagnostics products that address important health problems around the world. They are focusing on the development of DNA-based tests using Transrenal DNA or Tr-DNA.

Tr-DNAs are fragments of DNA derived from dying cells inside the body compartment. The intact DNA is fragmented in these dying cells, and then appears in the bloodstream. These fragments have been shown to cross the kidney barrier and can be detected in urine. Xenomics’ technology uses safe and simple urine collection to be applied to a broad range of testing, such as tumor detection, tissue transplants, infectious disease, even bio-terrorism.

Even though their stock performance in the past 3 months (see above) does not really look enticing, judging from the technology that they are currently developing – this stock can potentially be a good long-term investment. Let me give you a little bit of summary of their technology:

A particularly important feature of Tr-DNA diagnostic technology is that it is a true platform technology. This means that a single laboratory testing procedure designed to detect specific DNA biomarkers can be used to detect many forms of infectious diseases, cancer, transplanted cells and organs, or even prenatal detection of genetic markers of a fetus.

Tr-DNA tests are based upon a simple proprietary method of DNA isolation, followed by detection of DNA fragments bearing specific genetic markers. The detection methods and techniques are already well known and proven in molecular diagnostics laboratories where they are used to detect DNA in blood and a wide variety of specimens. Now these techniques are readily applied to the detection of Tr-DNA markers isolated from urine specimens. Thus, Tr-DNA technology may be applied to detecting and monitoring an extremely broad spectrum of medical conditions.

Additional advantages include:

  • The kidney acts as a filter and presents purified Tr-DNA in the urine and, therefore, simplifies the sample preparation and DNA isolation steps currently required in the laboratory by other testing methods.
  • The collection procedure is non-invasive and, therefore:
  • Does not require the involvement of trained medical staff, and
  • Easily supports repeated tests when conditions require and results in no discomfort for the patient.
  • The Xenomics technology utilizes existing analytical equipment readily available in diagnostic laboratories through the world. Any new capital spending would be limited.
  • Tr-DNA is stable at room temperature for extended periods. DNA in blood and many other traditional samples are not.
  • Test processing can often be easily automated.
  • Although many clinical Tr-DNA tests are performed using only a few drops of urine, it is readily possible to isolate these markers from larger volumes and thus increase the sensitivity of the test. This cannot be done easily using blood or tissue specimens.
  • In many instances, blood or sputum for detection of infectious diseases cannot be easily obtained from many patients such as small children or the elderly. Urine specimens are not often a problem.
  • Blood and other bodily fluids are highly infectious by nature, urine is not.

So…What do you think?

Source: xenomics.com

Quote of the Day:
Money may be the husk of many things but not the kernel. It brings you food, but not appetite; medicine, but not health; acquaintance, but not friends; servants, but not loyalty; days of joy, but not peace or happiness. – Henrik Ibsen

  • Share/Bookmark

Oct

16

Biotech Holdings, Inc. (Symbol: BIOHF)

Filed Under Biotechnology & Drugs | Leave a Comment

Biotech Holdings Ltd. is an integrated pharmaceutical company based in Vancouver, Canada, engaged in research, development, manufacture and marketing of pharmaceutical products.

The focus of the Company is the manufacturing and international marketing of SucanonTM, a new drug for the treatment of Type II Diabetes. Also known as Glucanin. The Company’s focus remains the development and distribution of Sucanon, particularly in Mexico and Latin America. During the fiscal year ended March 31, 2005, Biotech Holdings Ltd. began the manufacture of Sucanon.

In December 2004, the Company began shipping its Type II Diabetes drug Sucanon to Mexican retailers. On March 3, 2005, the Company announced that there was an expansion in the number of drugstore chains and other retail outlets carrying Sucanon in Mexico. Biotech Holdings Ltd. owns 75% of Smith Rothe Pharmaceutical Inc. (Smith Rothe). Smith Rothe holds the marketing rights for the Company’s Type II Diabetes drug in countries other than Asian Countries.

Following are a few of their investment highlights:

  • Sucanon is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called “insulin sensitizers”.
  • Sucanon has received regulatory approval in Mexico. Mexico is the eighth largest pharmaceutical market and one of the largest diabetic markets in the world. Complications of diabetes is Mexico’s leading cause of death.
  • Sales of the drug began in Mexico in early 2005. Sucanon is now sold in more than 600 stores nationally in Mexico including outlets of at least six drugstore chains.
  • Sucanon has been approved in Peru and sales are planned to begin later this year. Preliminary distribution agreements for Sucanon have been negotiated in other Latin American countries.
  • Internet sales of Sucanon are also planned.

The current trading price is very low, which is merely $0.05/share. It’s been fluctuating so much starting January 2006 and slowly declining – even though it once went up as high as $0.11/share in August, it quickly dropped again and finally settled at $0.05/share. I personally like the product that they currently develop; however, looking at their stock perfomance in the past 9 months, I have become very hesitant whether I should invest in this stock or not. Hmm..I’ll probably put this one under my stock-watch list and see what is going to happen in the next few months. Yup, we’ll see…….

Source: http://finance.google.com

Quote of the Day:
Each time, it’s a nice little company, nice people, modestly successful. Then you bring in the VC money – it’s like putting jet engines on a VW. They expect that, within a year and a half, they will get back ten times their money. – Dennis Faust

  • Share/Bookmark

Apr

16

Another Investment Opportunity in Healthcare Sector

Filed Under Biotechnology & Drugs | Leave a Comment

I’ve been watching this stock for the past 2 months now, and I guess this is the perfect time to write about them.

Carrington Labs Inc. (Symbol: CARN) is a bio-tech company which is currently engaged in the development, manufacturing, and marketing of naturally derived complex carbohydrates and other natural product therapeutics for the treatment f major illnesses, the dressing and management of wounds and nutritional supplements.

They consist of three business divisions:

  • Medical Services Division – The division that sells prescription and non-prescription medical products. They also provide manufacturing services to the medical markets
  • Consumer Services Division – Sells consumer and bulk raw material products and offers product development and manufacturing services to the cosmetic and nutraceutical markets
  • DelSite Biotechnologies Inc. – a wholly owned subsidiary that operates independently from the Company’s research and development program, and is responsible for the research, development and marketing of the Company’s GelSite technology

Even though they reported revenue of $28 million for the year 2005, they actually experienced net loss of $5.3 million and that was resulted from increased research and development expenses. Their revenue actually declined by $2 million compared to 2004 revenue.

However, their stock price has actually gone up by $1 since I started monitoring them – which was sometime in February. Had I bought 1,000 shares of them back in February (at $4.66/share), I would’ve made profit of $950 by now (it’s currently traded at $5.61/share). That’s actually not bad at all – considering it’s free money.

Here’s their price history for the period of January – April:

As you can see, the price started climbing at then end of February and it was fluctuating a lot once it’s passed $5/share. However, it was still able to make its way up to $7/share and now currently hovers over $6. I still believe it’s going to go back up to $8/share (maybe once their revenue for Q1 2006 increases). We’ll see what’s going to happen in the next few months..

Quote of the Day:
The trend is your friend. – Technical analysis motto

  • Share/Bookmark

Next Page →

ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f